Operating as a biopharmaceutical company, Sionna Therapeutics, Inc. is dedicated to transforming the treatment landscape for individuals with cystic fibrosis. This is achieved by developing innovative medicines designed to restore the normal function of the cystic fibrosis transmembrane conductance regulator.
| Metric | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|
| Revenue | N/A | N/A | N/A |
| Cost of Revenue | $668.00K | N/A | N/A |
| Gross Profit | $-668.00K | N/A | N/A |
| Gross Margin | 0.00% | 0.00% | 0.00% |
| Operating Expenses | $69.89M | $50.33M | $41.37M |
| Operating Income | $-70.56M | $-50.33M | $-41.37M |
| Operating Margin | 0.00% | 0.00% | 0.00% |
| Net Income | $-61.69M | $-47.26M | $-40.24M |
| Net Margin | 0.00% | 0.00% | 0.00% |
| EPS (Basic) | $-1.40 | $-1.07 | $-0.91 |
| EBITDA | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A |